Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
16
Participants
Timeline
Start Date
February 14, 2017
Primary Completion Date
March 29, 2017
Study Completion Date
April 11, 2017
Conditions
Healthy Participants
Interventions
DRUG
E2609
tablet
DRUG
Placebo
tablet
Trial Locations (1)
Unknown
Eisai Trial Site, Fukuoka
All Listed Sponsors
lead
Eisai Co., Ltd.
INDUSTRY
NCT03055962 - Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects | Biotech Hunter | Biotech Hunter